EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of C646‐Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300

Francesco Fiorentino iD, Filippo Spriano iD, Daniela Tomaselli iD, Giorgia Risi, Emanuele Fabbrizi iD, Valeria Pecci iD, Simona Nanni iD, Francesco Bertoni iD, Dante Rotili iD, Antonello Mai iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202400792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Francesco Fiorentino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy. Hauptthemen laut MEDLINE: Thalidomide, Antineoplastic Agents, p300-CBP Transcription Factors, E1A-Associated p300 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University, Sapienza University of Rome, Regione Lazio.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The alteration of the lysine acetyltransferase activity and protein–protein interactions of the transcriptional co‐activators CREB‐binding protein (CBP) and p300 is linked to the development of both solid and hematological cancers. To target both functions of CBP/p300, two PROTAC‐based chemical degraders are developed by linking the CBP/p300 catalytic inhibitor C646 and the Cereblon (CRBN) ligand thalidomide via polyethylene glycol‐based linkers. Both compounds exhibit submicromolar inhibition of CBP/p300 and decrease their levels in the SU‐DHL‐10 lymphoma cell line at low‐micromolar concentrations. Moreover, it is demonstrated that compound 1 recruits CBP/p300 and CRBN in cells and acts as a bona fide PROTAC degrader of CBP/p300 via the ubiquitin‐proteasome pathway. Finally, both compounds exhibit low‐micromolar antiproliferative activity in different lymphoma cell lines and are more potent than C646. Overall, it is demonstrated that the PROTAC strategy is a viable option for targeting CBP/p300 in lymphoma and identifies compound 1 as a promising chemical tool and lead compound for further studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideAntineoplastic Agentsp300-CBP Transcription FactorsE1A-Associated p300 ProteinCREB-Binding ProteinDrug DevelopmentEnzyme InhibitorsHumansProteolysisCell ProliferationStructure-Activity RelationshipCell Line, TumorMolecular StructureDrug Screening Assays, AntitumorDose-Response Relationship, DrugProteolysis Targeting ChimeraNitrobenzenesBenzoatesPyrazolonesUbiquitin-Protein LigasesAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

acetylationepigeneticslymphomaproteolysis targeting chimerastargeted degradation

Substanzen

Thalidomide4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acidAntineoplastic Agentsp300-CBP Transcription FactorsE1A-Associated p300 ProteinCREB-Binding ProteinCRBN protein, humanEP300 protein, humanEnzyme InhibitorsCREBBP protein, human

Autor:innen und Institutionen

  • Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.
  • Faculty of Biomedical Sciences, Institute of Oncology Research, USI Bellinzona, 6500, Bellinzona, Switzerland.
  • Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
  • Fondazione "Policlinico Universitario A. Gemelli IRCCS", 00168, Rome, Italy.
  • Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale Bellinzona, 6500, Bellinzona, Switzerland.
  • Department of Science, "Roma Tre" University, V.le G. Marconi 446, 00146, Rome, Italy.

ORCID-Profile: Francesco Fiorentino, Filippo Spriano, Daniela Tomaselli, Emanuele Fabbrizi, Valeria Pecci, Simona Nanni, Francesco Bertoni, Dante Rotili, Antonello Mai

Förderung

  • Italian Ministry of University
  • Sapienza University of Rome
  • Regione Lazio
  • AIRC
  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Fiorentino, F., Spriano, F., Tomaselli, D., Risi, G., Fabbrizi, E., Pecci, V., Nanni, S., Bertoni, F., Rotili, D., & Mai, A. (2025). Development of C646‐Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300. ChemMedChem. https://doi.org/10.1002/cmdc.202400792

Vancouver

Fiorentino F, Spriano F, Tomaselli D, Risi G, Fabbrizi E, Pecci V, et al. Development of C646‐Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300. ChemMedChem. 2025. doi:10.1002/cmdc.202400792

BibTeX
@article{Fiorentino2025,
  author = {Fiorentino, Francesco and Spriano, Filippo and Tomaselli, Daniela and Risi, Giorgia and Fabbrizi, Emanuele and Pecci, Valeria and Nanni, Simona and Bertoni, Francesco and Rotili, Dante and Mai, Antonello},
  title = {Development of C646‐Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202400792}
}
Kostenlos starten →